PDE4B/D-IN-5
PDE4B/D-IN-5 (Compound P32) is a peripherally restricted, oral active inhibitor of PDE4B and PDE4D with extremely low blood-brain barrier penetration, with IC50 values of 3.4 nM and 2.2 nM, respectively. PDE4B-IN-8 inhibits the production of TNF-α. PDE4B/D-IN-5 significantly reduces the Bax/Bcl2 ratio, and alleviates oxidative stress by decreasing MPO activity and NO levels. PDE4B/D-IN-5 exhibits anti-inflammatory, antioxidant, and anti-apoptotic activities. PDE4B/D-IN-5 can be used for the research of acute lung injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3064814-26-9
- Formule: C22H21F2N5O2
- Masse moléculaire:425.43
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
PDE4B1 3.4 nM (IC50) |
PDE4D3 2.2 nM (IC50) |
In Vitro
PDE4B/D-IN-5 potently inhibits recombinant PDE4B1 in an in vitro fluorescence polarization enzyme activity assay (IC50 = 3.4 nM)[1].
PDE4B/D-IN-5 (15 μM; up to 90 min) exhibits high metabolic stability in rat liver microsomes, with 94.8% remaining after 60 min, a half-life of 5.5 h, and a clearance as low as 0.0021 mL min−1 mg−1[1].
PDE4B/D-IN-5 (1-4 μM; 1 h) dose-dependently inhibits LPS-stimulated TNF-α production in RAW264.7 mouse macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:1-4 μM
-
Incubation Time:1 h
-
Result:Reduced supernatant TNF-α levels in a dose-dependent manner compared to the LPS-induced model group (which had TNF-α levels of 26 pg/mL, vs baseline 9 pg/mL in untreated cells).
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | AUC0-t | AUC0-∞ | T1/2 | MRT |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1 (plasma) mg/kg | i.v. | 4.98 min | 7665.53 ng/mL | 5661.94 ng·h/mL | 5735.78 ng·h/mL | 1.26 h | 1.09 h |
| Mice[1] | 25 (plasma) mg/kg | p.o. | 36 min | 46941.22 ng/mL | 111577.48 ng·h/mL | 127646.89 ng·h/mL | 2.45 h | 3.40 h |
| Mice[1] | 1 (brain) mg/kg | i.v. | 9.98 min | 49.69 ng/mL | 73.90 ng·h/mL | 80.96 ng·h/mL | 2.07 h | 2.71 h |
In Vivo
PDE4B/D-IN-5 (6-12 mg/kg; i.p.; daily; 5 days) dose-dependently attenuates LPS-induced acute lung injury in male C57BL/6 mice via anti-inflammatory, antioxidant, and antiapoptotic effects mediated by the cAMP-Epac pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (male, 8 weeks old, acute lung injury model via intratracheal LPS instillation)[1]
-
Dosage:6 mg/kg; 12 mg/kg
-
Administration:i.p.; daily; 5 days
-
Result:Reduced lung erythema, enlargement, alveolar damage, interstitial edema, and inflammatory cell infiltration.
Showed a significant reduction in Smith lung injury scores in the 12 mg/kg group compared to the model group.
Reduced lung wet/dry weight ratios with a dose-dependent trend.
Reduced bronchoalveolar lavage fluid (BALF) neutrophil counts more effectively than dexamethasone, with a dose-dependent effect.
Attenuated lung myeloperoxidase (MPO) activity more potently than dexamethasone, with a dose-dependent effect.
Reduced lung tissue nitric oxide (NO) levels to values comparable to dexamethasone.
Suppressed BALF tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) levels in a dose-dependent manner, with the 12 mg/kg group showing greater suppression than dexamethasone.
Dose-dependently elevated lung tissue cAMP levels, with the 12 mg/kg group showing the most pronounced effect.
Induced a dose-dependent, significant upregulation of Epac1 protein expression.
Significantly decreased the Bax/Bcl2 ratio, indicating suppression of mitochondrial apoptosis.
Showed no statistically significant changes in p-PKA/PKA or p-AMPK/AMPK ratios.
Chemical Information
-
CAS No. 3064814-26-9
-
Masse moléculaire 425.43
-
Formule C22H21F2N5O2
-
SMILES
FC([H])(CN1N=C(C2=CC=NN2CC)C3=C1C=CC(NC4=CC=C(CC(O)=O)C=C4)=C3)F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)